Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $26.9600 (1.18%) ($26.9600 - $26.9600) on Tue. Aug. 31, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.37% (three month average) | RSI | 73 | Latest Price | $26.9600(1.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1% a day on average for past five trading days. | Weekly Trend | TGTX advances 8.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(61%) ARKK(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.185% in a week (0% probabilities). VIXM(-47%) VXX(-39%) UUP(-20%) IGOV(-7%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.185% (StdDev 4.37%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $26.39(2.16%) | 10 Day Moving Average | $25.3(6.56%) | 20 Day Moving Average | $24.17(11.54%) | To recent high | -33.4% | To recent low | 24.4% | Market Cap | $3.414b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |